Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sandea Greene-Harris

Neurological Surgery Stockbridge, GA Medical Doctor

NPI 1295784429 CMS profile 58973

203 Medical Blvd, Stockbridge, GA 30281

Open in the dashboard

General payments

$77,299

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sandea Greene-Harris of Stockbridge, GA is reported in the CMS Open Payments database as having received $77,299 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,964 47
2024 General $9,015 24
2023 General $644 14
2022 General $14,852 25
2021 General $6,654 5
2020 General $26,992 14
2019 General $3,177 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandea Greene-Harris
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Sandea Greene-Harris were reported at $15,964. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Sandea Greene-Harris Neurological Surgery median Middle half National median
2019 $3,177 $582 $138–$3,006 $163
2020 $26,992 $294 $76–$2,174 $114
2021 $6,654 $387 $105–$2,432 $132
2022 $14,852 $542 $139–$2,989 $149
2023 $644 $534 $145–$2,697 $160
2024 $9,015 $574 $155–$3,046 $164
2025 $15,964 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $44,008 64 payments
  2. Stryker Corporation $30,051 33 payments
  3. SI-BONE, Inc. $1,032 7 payments
  4. DePuy Synthes Sales Inc. $696 10 payments
  5. Boston Scientific Corporation $491 6 payments
  6. Globus Medical, Inc. $454 6 payments
  7. Nevro Corp. $121 2 payments
  8. Smith+Nephew, Inc. $74 2 payments
  9. Inspire Medical Systems, Inc. $64 2 payments
  10. Bioventus LLC $53 2 payments
  11. Other $255 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $65,167 20 payments
  2. Travel and Lodging $7,490 36 payments
  3. Food and Beverage $4,642 90 payments
Products named General payments · program years 2019–2025
  1. TRITANIUM $25,880 19 payments
  2. ES2 $24,936 14 payments
  3. STEALTHSTATION S8 PLATFORM $22,527 25 payments
  4. SERRATO $15,810 9 payments
  5. AERO $15,810 9 payments
  6. LATERAL ACCESS SPINAL SYSTEM $9,423 6 payments
  7. CASCADIA $9,423 6 payments
  8. STEALTH AUTOGUIDE SYSTEM $8,974 13 payments
  9. StealthStation $6,500 4 payments
  10. XIA $1,506 4 payments
  11. Other $7,352 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

149

Median for Neurosurgery: 83

Drug cost

$1,065

Median for Neurosurgery: $872

Branded share of claims

36.9%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 40 $256
Pregabalin Generic 12 $222
Gabapentin Generic 23 $185
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $126
Meloxicam Generic 17 $102
Cyclobenzaprine Hcl Generic 24 $93
Tramadol Hcl Generic 18 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$72,040

Medicare's payments for the services billed

Medicare patients

122

Average age 72

Services billed

276

71 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 42%
Chronic kidney disease 42%
Ischemic heart disease 36%
Depression 29%
Heart failure 27%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record